Based on the authorization granted by the Annual General Meeting on 21 April 2026, the Board of Directors of Nanoform has on 29 May 2026 resolved to issue stock options to selected key employees of the company, other than members of senior management. The stock options are offered in deviation from the shareholders' pre-emptive subscription right. The stock options are issued free of charge.

There is a weighty financial reason from the company’s point of view to issue stock options as provided in Chapter 10, Section 1 of the Finnish Limited Liability Companies Act, because the stock options are issued in order to commit key individuals to the company.

The total number of option rights to be issued is at most 420,000. The stock options entitle to subscribe for at most 420,000 shares in Nanoform. Each stock option entitles to subscribe for one new share. The subscription price for shares subscribed with stock options is EUR 1.70 per share, which is approximately 70 percent more than the closing price on 28 May 2026. The total subscription price of the shares shall be paid to the company’s fund for invested own free equity.

The theoretical market value of the program is estimated at approximately EUR 140 thousand, which is 420,000 times the value of one stock option. The value of one stock option has been calculated using the Black-Scholes option pricing model. The following assumptions have been used to determine the value of the option: share price EUR 1.00, stock option exercise price EUR 1.70, maturity 5 years, risk-free interest rate 4 percent and volatility 50 percent.

The subscription period for shares based on the option rights shall commence from the registration of stock options to the Trade Register and ends on 29 May 2031.

The stock options entitle to subscribe for shares during the subscription period in accordance with the subscription schedule agreed in the option agreement between Nanoform and each option holder so that all issued stock options entitle option holders to subscribe for shares at the latest on 29 May 2027. If the option holder’s employment or service relationship or membership in the board of directors with Nanoform or a company within the same group as Nanoform terminates, any stock options, for which the subscription period, as may be separately agreed with the option holder, has not commenced; or in the absence of such agreement, all stock options, shall become void immediately as from the date of the notice of termination regarding the relationship without compensation and for all such stock options for which the subscription period has commenced, the option holder must subscribe for shares in Nanoform with such stock options within 90 days from the notice of termination of the relationship, following which any remaining stock options shall become void without compensation, unless otherwise resolved by the board of directors of Nanoform.

For further information, please contact:
Albert Haeggström, CFO
albert.haeggstrom@nanoform.com
+358 29 370 0150

For investor relations queries, please contact:
Henri von Haartman, Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11

About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@dnbcarnegie.se. For more information, please visit www.nanoform.com.